Bausch + Lomb BLCO Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Business | |||||
| Pharmaceuticals | $1.08B+11.6% | $969M+56.8% | $618M+32.1% | $468M-5.1% | |
| Surgical | $894M+6.0% | $843M+9.9% | $767M+6.8% | $718M0.0% | |
| Vision Care | $2.92B+6.7% | $2.74B+7.7% | $2.54B+7.3% | $2.37B+1.8% | |
| Operating Income (Loss) by Business | |||||
| Pharmaceuticals | $258M+0.8% | $256M+6.2% | $241M+18.7% | $203M-32.6% | |
| Surgical | $18M-59.1% | $44M-12.0% | $50M+19.0% | $42M-44.0% | |
| Vision Care | $849M+5.1% | $808M+17.3% | $689M+8.3% | $636M+10.4% | |
| Selling, general and administrative (Note 4) by Business | |||||
| Pharmaceuticals | $572M+5.3% | $543M+68.6% | $322M+40.0% | $230M— | |
| Surgical | $298M+12.5% | $265M+6.9% | $248M+7.4% | $231M— | |
| Vision Care | $912M+3.4% | $882M+6.0% | $832M+6.1% | $784M— | |
| R&D by Business | |||||
| Pharmaceuticals | $53M+60.6% | $33M+65.0% | $20M-31.0% | $29M— | |
| Surgical | $43M+2.4% | $42M+20.0% | $35M-7.9% | $38M— | |
| Vision Care | $48M+4.3% | $46M-31.3% | $67M+19.6% | $56M— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | |||||
| Pharmaceuticals | -$105M-314% | $49M— | —— | $30M+114% | |
| Surgical | -$13M-360% | $5M— | —— | —— | |
| Goodwill by Business | |||||
| Pharmaceuticals | $2.91B+8.3% | $2.69B— | —— | —— | |
| Surgical | $1.54B+15.7% | $1.33B+3.0% | $1.29B+4.5% | $1.23B— | |
| Vision Care | $14.2B+0.2% | $14.17B-0.2% | $14.21B0.0% | $14.21B— | |
| Total revenues by Product | |||||
| Branded and Other Generics | $242M-13.9% | $281M+11.5% | $252M+2.9% | $245M-3.5% | |
| Devices | $1.92B+6.8% | $1.8B+9.1% | $1.65B+5.0% | $1.57B-1.5% | |
| OTC | $1.84B+6.4% | $1.72B+7.0% | $1.61B+10.3% | $1.46B+4.8% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | |||||
| Other revenues | $5M+25.0% | $4M+100% | $2M-75.0% | $8M-11.1% | |
| Product sales | $2.05B+9.5% | $1.87B+13.9% | $1.64B+8.5% | $1.51B+3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch + Lomb break its business down?
- Bausch + Lomb (BLCO) reports total revenues by business across 3 parts — Pharmaceuticals, Surgical and Vision Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch + Lomb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch + Lomb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.